What is the clinical evidence from this study?

Study design: Systematic Review. Population: Primary and secondary cardiovascular prevention. Intervention: Statin therapy discontinuation vs. Statin therapy continuation. Primary outcome: All-cause and cardiovascular mortality (HR 1.30 to 4.65).

What does this research mean for the field?

Up to half of patients discontinue statin therapy within the first year due to factors such as fear of side effects and misinformation, which is associated with significantly higher all-cause and cardiovascular mortality. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the prevalence, underlying causes, and clinical outcomes associated with statin therapy discontinuation in primary and secondary cardiovascular prevention.

August 26, 2026MetabolitesOpen Access

The Statin Paradox: Drivers and Consequences of Therapy Discontinuation

View Full Paper

Ask AI

Bookmark

Key result

Statin discontinuation occurs in up to ~50% of patients and is linked to higher mortality.

HR 1.30 to 4.65

Why the study?

What are the rates, drivers, and clinical consequences of statin therapy discontinuation in patients on primary or secondary prevention?

Population

Patients prescribed statin therapy for primary or secondary prevention (29 included observational studies)

Comparison

Statin therapy discontinuation vs Statin therapy continuation

Design

Systematic_review

Authors

ADAdrianna DylikPoznan University of Medical Sciences MMMikołaj MusiałPoznan University of Medical Sciences MRMichał RadkePoznan University of Medical Sciences

Discussion

Member takes

Implication

Statin discontinuation is highly prevalent and driven by side effects and misinformation, leading to a substantial increase in mortality and cardiovascular events.

Key Points

To evaluate the prevalence, underlying causes, and clinical outcomes associated with statin therapy discontinuation in primary and secondary cardiovascular prevention.
Systematic review of 29 observational studies published since January 1, 2014, identified via PubMed and Google Scholar adhering to PRISMA guidelines (PROSPERO CRD420261295172).
Methodological quality and risk of bias were evaluated using the Newcastle–Ottawa Scale and Joanna Briggs Institute Critical Appraisal Tools.
First-year discontinuation rates ranged from 27.1% to 47.0% in primary prevention cohorts and 18.5% to 32.4% in secondary prevention cohorts, driven by fear of statin-associated muscle symptoms, misinformation, limited physician communication, and polypharmacy.
Statin discontinuation was associated with significantly higher all-cause and cardiovascular mortality (HR ranging from 1.30 to 4.65), elevated cardiovascular and cerebrovascular event rates, poorer metabolic outcomes, and increased healthcare costs.

Study Design

Type

Systematic Review

Structured PICO

What are the rates, drivers, and clinical consequences of statin therapy discontinuation in patients on primary or secondary prevention?

Population

Systematic review of 29 observational studies evaluating the drivers and consequences of statin therapy discontinuation in primary and secondary prevention.

Exposure

Statin therapy discontinuation

Comparator

Statin therapy continuation

Outcome

Rates of discontinuation, drivers of non-adherence, and clinical consequences including all-cause and cardiovascular mortalityhard clinical

Main Result

Effect estimate: HR 1.30 to 4.65

Statin discontinuation is highly prevalent and driven by side effects and misinformation, leading to a substantial increase in mortality and cardiovascular events.

Cite This Study

Dylik et al. (2026) conducted a systematic review in Primary and secondary cardiovascular prevention. Statin therapy discontinuation vs. Statin therapy continuation was evaluated on All-cause and cardiovascular mortality (HR 1.30 to 4.65). Statin therapy discontinuation occurs in up to half of patients within the first year and is associated with significantly higher all-cause and cardiovascular mortality (HR 1.30 to 4.65).

synapsesocial.com/papers/6a8e9bcc451774b83f3b4aef https://doi.org/10.3390/metabo16090603

View Full Paper

Ask AI

Bookmark

Implication

Statin discontinuation is highly prevalent and driven by side effects and misinformation, leading to a substantial increase in mortality and cardiovascular events.

The Statin Paradox: Drivers and Consequences of Therapy Discontinuation

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

The Statin Paradox: Drivers and Consequences of Therapy Discontinuation

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider